Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 83

Sort by

Sort Order Select

Journal Articles

What’s new in the pathogenesis and treatment of therapy-related myeloid neoplasms

Maria Teresa Voso, Giulia Falconi, Emiliano Fabiani

Blood (2021) 138 (9): 749–757.

https://doi.org/10.1182/blood.2021010764

Published: 2021

Journal Articles

How I treat acute myeloid leukemia in the era of new drugs

Courtney D. DiNardo, Andrew H. Wei

Blood (2020) 135 (2): 85–96.

https://doi.org/10.1182/blood.2019001239

Published: 2020

Includes: Supplemental data

Journal Articles

A Descriptive Study on Healthcare Utilization and Costs in Secondary Acute Myeloid Leukemia Patients Treated with CPX-351 Versus Those Treated with 7+3

Kwanza Price, MPH, Zhun Cao, PhD, Craig Lipkin, Scott Robinson, Deborah Ann Profant, PhD

Blood (2019) 134 (Supplement_1): 2213.

https://doi.org/10.1182/blood-2019-127075

Published: 2019

Journal Articles

Restoring Functional Deficits in Older Adults with Hematologic Malignancy

Ashley E. Rosko, MD, Sarah A Wall, MD, Robert A Baiocchi, MD PhD, Don M. Benson, Jr., MD PhD, Jonathan E. Brammer, MD, John C. Byrd, MD, Yvonne A. Efebera, MD MPH, Kami J. Maddocks, MD, Kerry A. Rogers, MD, Carolyn Presley, MD, Desiree Jones, Ying Huang, MS, MA, Michelle Naughton, PhD MPH

Blood (2019) 134 (Supplement_1): 4776.

https://doi.org/10.1182/blood-2019-130531

Published: 2019

Journal Articles

Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Jeffrey E. Lancet, MD, David A. Rizzieri, MD, Gary J. Schiller, MD, Scott R. Solomon, MD, Laura F. Newell, MD, Harry P. Erba, MD PhD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 1313.

https://doi.org/10.1182/blood-2019-124383

Published: 2019

Journal Articles

Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylating Agent Exposure Who Achieved Remission

Tara L. Lin, MD, Daniel H. Ryan, MD, Ellen K. Ritchie, MD, Stephen A. Strickland, MD, Donna E. Hogge, MD PhD, Scott R. Solomon, MD, Jonathan E. Kolitz, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD PhD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 1316.

https://doi.org/10.1182/blood-2019-124552

Published: 2019

Journal Articles

CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations ( TP53, ASXL1, RUNX1 and EVI1 ) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort

Blood (2019) 134 (Supplement_1): 1355.

https://doi.org/10.1182/blood-2019-125623

Published: 2019

Journal Articles

Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor ± Mitoxantrone (CLAG ± M) Is Highly Effective Therapy for Secondary and Relapsed/Refractory Acute Myeloid Leukemia

Amanda Przespolewski, DO, Craig W. Freyer, PharmD, Wenyan Ji, MA, Tara L. Cronin, BA, Swapna Thota, MD, Elizabeth A. Griffiths, MD, James E. Thompson, MD, Amro Elshoury, MBBChir, Jeffrey Baron, PharmD, Mark Walsh, PharmD, Eunice S. Wang, MD

Blood (2019) 134 (Supplement_1): 1361.

https://doi.org/10.1182/blood-2019-130582

Published: 2019

Journal Articles

Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

Ravi Vij, MBBS, Thomas G. Martin, III, MD, Nitya Nathwani, MD, Mark A. Fiala, BS, Feng Gao, PhD, Abhinav Deol, MD, Francis K. Buadi, MB, CHB, Jonathan L. Kaufman, MD, Craig C Hofmeister, MDMPH, Tara K. Gregory, MD, Jesus G. Berdeja, MD, Ajai Chari, MD, Ashley E. Rosko, MD

Blood (2019) 134 (Supplement_1): 602.

https://doi.org/10.1182/blood-2019-130644

Published: 2019

Journal Articles

Multi-Center Retrospective Evaluation of High-Dose Cytarabine Based Induction Versus CPX-351 Induction in Patients with Secondary AML

Lydia Benitez, PharmD, Anthony J. Perissinotti, PharmD, Caitlin R. Rausch, PharmD, Jeff Klaus, PharmD, Stephen Michael Clark, PharmD, Michael Filtz, PharmD, Kelley L Ratermann, PharmD, Carissa F. Treptow, PharmD, Shawn Griffin, PharmD, Marissa Olson, PharmD, Mallory Crain, PharmD, Kristen Pettit, MD, Patrick W. Burke, MD, Dale L. Bixby, MD, Bernard Lawrence Marini, PharmD

Blood (2019) 134 (Supplement_1): 2639.

https://doi.org/10.1182/blood-2019-122189

Published: 2019

Journal Articles

Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Blood (2019) 134 (Supplement_1): 2642.

https://doi.org/10.1182/blood-2019-129137

Published: 2019

Journal Articles

Daratumumab-Mediated Lymphocyte Kinetics Predict Adverse Events and Survival Outcomes in Patients with Multiple Myeloma

Francesca Cottini, MD, Nita Williams, Naresh Bumma, MD, Abdullah Mohammad Khan, MBBS, MSc, Maria Chaudhry, MD, Srinivas Devarakonda, MD, Yvonne A. Efebera, MD MPH, Don M. Benson, Jr., MD PhD, Ashley E. Rosko, MD

Blood (2019) 134 (Supplement_1): 5501.

https://doi.org/10.1182/blood-2019-129128

Published: 2019

Journal Articles

Donor Cell Acute Myeloid Leukemia after Transplant for Follicular Lymphoma

Lacey S. Williams, MD, Catherine E. Lai, MD

Blood (2019) 134 (Supplement_1): 5697.

https://doi.org/10.1182/blood-2019-122932

Published: 2019

Journal Articles

The Effect of Cytogenetic Abnormalities on Organ Involvement and Survival in Patients with AL Amyloidosis

Michael Ozga, MD, Qiuhong Zhao, MS, Don M. Benson, Jr., MD PhD, Patrick Elder, MS, Nita Williams, Naresh Bumma, MD, Ashley E. Rosko, MD, Maria Chaudhry, MD, Abdullah Mohammad Khan, MBBS,MSc, Srinivas Devarakonda, MD, Rami Kahwash, MD, Ajay Vallakati, MD, Courtney Campbell, MD PhD, Samir Parikh, MD, Salem Almaani, MD, Jason Prosek, MD, Elyse Redder, PT, CLT-LANA, Yvonne A. Efebera, MD MPH, Nidhi Sharma, PhD

Blood (2019) 134 (Supplement_1): 1833.

https://doi.org/10.1182/blood-2019-124206

Published: 2019

Journal Articles

Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS)

Jorge Cortes, MD, Guillermo Garcia-Manero, MD, Koji Sasaki, MD, Kiran Naqvi, MDMPH, Yesid Alvarado, MD, Tapan M. Kadia, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Naval G. Daver, MD, Koichi Takahashi, MD, Elias Jabbour, MD, Gautam M. Borthakur, MD, Naveen Pemmaraju, MD, Marina Y Konopleva, MD PhD, Sherry A. Pierce, BSN, BA, Carlos E. Bueso-Ramos, MD PhD, Keyur P. Patel, MBBS, PhD, Hagop M. Kantarjian, MD, Guillermo Montalban Bravo, MD

Blood (2019) 134 (Supplement_1): 1726.

https://doi.org/10.1182/blood-2019-126005

Published: 2019

Journal Articles

Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML)

R. Coleman Lindsley, MD PhD, Christopher J. Gibson, MD, H. Moses Murdock, BS, Richard M. Stone, MD, Jorge E. Cortes, MD, Geoffrey L. Uy, MD, Tara L. Lin, MD, Ellen K. Ritchie, MD, Thomas Prebet, MD PhD, Robert J. Ryan, MS, Stefan Faderl, MD, Jeffrey E. Lancet, MD

Blood (2019) 134 (Supplement_1): 15.

https://doi.org/10.1182/blood-2019-124500

Published: 2019

Journal Articles

Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)

Joseph Maakaron, MD, Qiuhong Zhao, MS, Marcin Puto, PharmD, Quinn Verfurth, Sam Penza, MD, Jonathan E Brammer, MD, Yvonne A. Efebera, MD MPH, Ashley E. Rosko, MD, Ayman Saad, MD, Samantha Jaglowski, MDMPH, Basem M. William, MRCP,MD

Blood (2019) 134 (Supplement_1): 2024.

https://doi.org/10.1182/blood-2019-126994

Published: 2019

Journal Articles

AL Amyloidosis: The Effects of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes

Blood (2019) 134 (Supplement_1): 2029.

https://doi.org/10.1182/blood-2019-130307

Published: 2019

Journal Articles

Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Shannon R. McCurdy, MD, Shannon H. Gier, BS, Daria V. Babushok, MD PhD, Noelle V. Frey, MD, Saar I. Gill, MD PhD, Elizabeth O. Hexner, MD, Alison W. Loren, MD MSCE, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Alexander E. Perl, MD, Ivan Maillard, MD PhD, Keith W. Pratz, MD, David L. Porter, MD, Martin P. Carroll, MD, Phyllis A. Gimotty, PhD, Selina M. Luger, MD FRCPC

Blood (2019) 134 (Supplement_1): 2209.

https://doi.org/10.1182/blood-2019-124468

Published: 2019

Journal Articles

Outcome of Patients with Newly-Diagnosed Therapy-Related AML (t-AML) and AML with Myelodysplasia-Related Changes (AML-MRC) Treated with Liposomal Daunorubicin and Cytarabine (CPX-351) at an Academic Community-Based Health System

John Khoury, MD, Nwabundo Anusim, MD, David Macari, MD, Angela Duenn, PharmD, Ishmael Jaiyesimi, DO, MS

Blood (2019) 134 (Supplement_1): 5117.

https://doi.org/10.1182/blood-2019-130776

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

What’s new in the pathogenesis and treatment of therapy-related myeloid neoplasms

How I treat acute myeloid leukemia in the era of new drugs

A Descriptive Study on Healthcare Utilization and Costs in Secondary Acute Myeloid Leukemia Patients Treated with CPX-351 Versus Those Treated with 7+3

Restoring Functional Deficits in Older Adults with Hematologic Malignancy

Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylating Agent Exposure Who Achieved Remission

CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations ( TP53, ASXL1, RUNX1 and EVI1 ) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort

Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor ± Mitoxantrone (CLAG ± M) Is Highly Effective Therapy for Secondary and Relapsed/Refractory Acute Myeloid Leukemia

Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

Multi-Center Retrospective Evaluation of High-Dose Cytarabine Based Induction Versus CPX-351 Induction in Patients with Secondary AML

Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Daratumumab-Mediated Lymphocyte Kinetics Predict Adverse Events and Survival Outcomes in Patients with Multiple Myeloma

Donor Cell Acute Myeloid Leukemia after Transplant for Follicular Lymphoma

The Effect of Cytogenetic Abnormalities on Organ Involvement and Survival in Patients with AL Amyloidosis

Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS)

Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML)

Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)

AL Amyloidosis: The Effects of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes

Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Outcome of Patients with Newly-Diagnosed Therapy-Related AML (t-AML) and AML with Myelodysplasia-Related Changes (AML-MRC) Treated with Liposomal Daunorubicin and Cytarabine (CPX-351) at an Academic Community-Based Health System

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only